Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 5/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487667 | 0.97 | PLA2G2A (0.40) | PLA2G2APPARG | |
| SCHEMBL6490551 | 0.92 | PLA2G2A (0.41) | PLA2G2ATHRATHRBPPARGCYSLTR2 | |
| SCHEMBL6490815 | 0.89 | CYSLTR2 (0.41) | PLA2G2APPARGCYSLTR2CYSLTR1 | |
| SCHEMBL7194795 | 0.87 | PPARG (0.40) | PLA2G2APPARDTHRBPPARGPPARA | |
| SCHEMBL6489614 | 0.86 | PLA2G4B (0.41) | PPARDPLA2G4BTHRATHRBPPARG | |
| SCHEMBL6500098 | 0.85 | PPARG (0.50) | PLA2G2APLA2G4BTHRATHRBPPARG | |
| SCHEMBL6497975 | 0.85 | PPARG (0.44) | PLA2G2APLA2G4BTHRATHRBPPARG | |
| SCHEMBL6491422 | 0.84 | PPARG (0.51) | PLA2G2APLA2G4BTHRATHRBPPARG | |
| SCHEMBL6491561 | 0.84 | PLA2G4B (0.40) | PLA2G2APLA2G4BTHRATHRBPPARG | |
| SCHEMBL6488344 | 0.83 | MCL1 (0.47) | PLA2G2APLA2G4BTHRATHRBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PLA2G2A 4801/4885PPARD 290/4885PLA2G4B 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.